ENTRY       D12434                      Drug
NAME        Valoctocogene roxaparvovec (USAN/INN);
            Valoctocogene roxaparvovec-rvox;
            Roctavian (TN)
PRODUCT     ROCTAVIAN (BioMarin Pharmaceutical)
CLASS       Blood modifier agent
             DG02016  Hemostatics
              DG02014  Blood coagulation accelerant
               DG02013  Blood coagulation factor
REMARK      Product: D12434<US>
EFFICACY    Bleeding suppressant
  DISEASE   Hemophilia A [DS:H00219]
  TYPE      Gene therapy product
COMMENT     Treatment of hemophilia A
TARGET      F8* [HSA_VAR:2157v1] [HSA:2157] [KO:K03899]
  PATHWAY   hsa04610(2157)  Complement and coagulation cascades
INTERACTION  
BRITE       Drug groups [BR:br08330]
             Blood modifier agent
              DG02016  Hemostatics
               DG02014  Blood coagulation accelerant
                DG02013  Blood coagulation factor
                 D12434  Valoctocogene roxaparvovec
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                F8* [HSA_VAR:2157v1]
                 D12434  Valoctocogene roxaparvovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12434
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12434
             Cellular and gene therapy products
              D12434
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12434
DBLINKS     CAS: 1819334-78-5
///
